Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7831 to 7845 of 8899 results

  1. Transurethral radiofrequency needle ablation of the prostate (IPG15)

    This guidance has been updated and replaced by NICE guideline CG97.

    Withdrawn guidance

  2. Foker technique for long-gap oesophageal atresia (IPG153)

    We have moved interventional procedures guidance 153 to become HealthTech guidance 98. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  3. Laparoscopic partial nephrectomy (IPG151)

    We have moved interventional procedures guidance 151 to become HealthTech guidance 97. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  4. KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication: early value assessment (HTE10)

    We have moved health technology evaluation 10 to become HealthTech guidance 694. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections (HTE1)

    We have moved HTE1 to become 'antimicrobial resistance guidance'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The guidance itself has not changed. See antimicrobial resistance guidance 1 on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn guidance

  6. Artificial intelligence (AI)-derived software to analyse chest X-rays for suspected lung cancer in primary care referrals: early value assessment (HTE12)

    We have moved health technology evaluation 12 to become HealthTech guidance 696. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  7. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment (HTE11)

    We have moved health technology evaluation 11 to become HealthTech guidance 695. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  8. Virtual reality technologies for treating agoraphobia or agoraphobic avoidance: early value assessment (HTE15)

    We have moved health technology evaluation 15 to become HealthTech guidance 701. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  9. Digital technologies for managing non-specific low back pain: early value assessment (HTE16)

    We have moved health technology evaluation 16 to become HealthTech guidance 712. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  10. Virtual ward platform technologies for acute respiratory infections: early value assessment (HTE13)

    We have moved health technology evaluation 13 to become HealthTech guidance 697. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  11. Digital technologies for delivering multidisciplinary weight-management services: early value assessment (HTE14)

    We have moved health technology evaluation 14 to become HealthTech guidance 700. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  12. Digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people: early value assessment (HTE17)

    We have moved Health technology evaluation 17 to become HealthTech guidance 713. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  13. Digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD: early value assessment (HTE18)

    We have moved Health technology evaluation 18 to become HealthTech guidance 718. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  14. Digital technologies to support self-management of COPD: early value assessment (HTE19)

    We have moved Health technology evaluation 19 to become HealthTech guidance 736. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  15. Cefiderocol for treating severe drug-resistant gram-negative bacterial infections (HTE2)

    We have moved HTE2 to become 'antimicrobial resistance guidance'. This is to better reflect what the purpose of this product is and to help you find relevant content more quickly. The guidance itself has not changed. See antimicrobial resistance guidance 2 on cefiderocol for treating severe drug-resistant gram-negative bacterial infections.

    Withdrawn guidance